All Articles

As Netcracker showcases its agentic AI in Düsseldorf, the telecom sector is at a crossroads. Is this the moment AI moves from a cost-saver to a core revenue driver?

Ourbit's new $3M campaign is more than a prize pool; it's a look into the new reality of crypto, where user loyalty is won through elaborate, gamified experiences.

Resalis Therapeutics poaches a top clinical leader from Novo Nordisk to steer its novel RNA-based obesity drug, RES-010, through clinical trials.

Amid a $5.8B expansion, Kuwait Airport is deploying advanced geospatial intelligence to map its nerve center, enhancing air safety and future-proofing operations.

As venture-backed giants falter, Work Heights marks 12 years of profitable, independent growth. Its Brooklyn-centric model offers a new playbook.

In a market plagued by doubt, one climate firm’s move to secure top-tier KPMG assurance for its internal controls is a strategic play to redefine credibility.

As coworking giants faltered, one Brooklyn company quietly thrived. Work Heights marks 12 years of bootstrapped growth, proving sustainability beats scale.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?

Fresh from bankruptcy, iRobot launches its most advanced Roomba. But in a market swamped by rivals, is this high-tech offensive enough to reclaim its throne?

Beyond national treaties, a Chinese hardware hub and an Armenian software powerhouse are forging a new kind of alliance. This is how city-level diplomacy is building the future.

PIMCO's consistent monthly distributions are a draw for income seekers, but a deep dive reveals the critical role of return of capital, leverage, and market risk.

A landmark deal for a traditional medicine ingredient is about more than wellness. It’s a calculated play to reshape Macau's future beyond the casino floor.

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

As specialty contractor MYR Group meets with top investors, its strategy reveals a bigger story: how firms building our green infrastructure are Wall Street's new darlings.

XAI's XFLT fund offers a steady dividend, a comfort to income investors. But beneath the surface, a strategic pivot to a new heavyweight sub-advisor aims to fix years of underperformance.

With massive acquisitions in Florida and beyond, PACS Group is growing at a breakneck pace. But is its REIT-fueled, 'locally led' model a new paradigm for care or a risky bet?

A new 347 MW solar farm breaks ground near Houston, but the real story is the strategic international alliance and corporate demand fueling Texas's future.

As Alamar Biosciences prepares for a key fireside chat at Morgan Stanley, all eyes are on its NULISA™ technology and its rapid commercial growth.

GitLab posts strong 21% revenue growth, leveraging its financial momentum to double down on AI and flexible enterprise models, navigating a complex market.